Renal cell carcinoma 4

Common Name(s)

Renal cell carcinoma 4

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma 4" returned 31 free, full-text research articles on human participants. First 3 results:

Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.
 

Author(s): Dagmar Quandt, Simon Jasinski-Bergner, Ulrike Müller, Bianca Schulze, Barbara Seliger

Journal:

 

The importance of B7-H molecules for the T cell/tumor communication and its impact on renal cell carcinoma (RCC) progression and prognosis has been recently described. Cytokine treatment of RCC has earlier been shown to be beneficial in preclinical settings, but its clinical implementation ...

Last Updated: 3 Jul 2014

Go To URL
Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
 

Author(s): Tsunenori Kondo, Toshio Takagi, Hirohito Kobayashi, Junpei Iizuka, Taiji Nozaki, Yasunobu Hashimoto, Eri Ikezawa, Kazuhiko Yoshida, Kenji Omae, Kazunari Tanabe

Journal: Jpn. J. Clin. Oncol.. 2014 Mar;44(3):270-7.

 

Poor tolerability to sunitinib with the standard dosing schedule has become an issue. We retrospectively analyzed the treatment efficacy and the profile of adverse events of 2 weeks of sunitinib treatment followed by 1-week-off (Schedule 2/1) and compared the results with the standard ...

Last Updated: 5 Mar 2014

Go To URL
Comparison of long-term results after nephron-sparing surgery and radical nephrectomy in treating 4- to 7-cm renal cell carcinoma.
 

Author(s): Daimantas Milonas, Giedrius Skulčius, Ruslanas Baltrimavičius, Stasys Auškalnis, Marius Kinčius, Aivaras Matjošaitis, Inga Gudinavičienė, Giedrė Smailytė, Mindaugas Jievaltas

Journal: Medicina (Kaunas). 2013 ;49(5):223-8.

 

The aim of our study was to compare long-term oncological outcomes following nephron-sparing surgery (NSS) and radical nephrectomy (RN) for renal cell carcinoma (RCC) 4 to 7 cm in diameter.

Last Updated: 19 Nov 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma 4" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
 

Status: Not yet recruiting

Condition Summary: Renal Cell Cancer

 

Last Updated: 28 Apr 2009

Go to URL
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
 

Status: Recruiting

Condition Summary: Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor

 

Last Updated: 31 Aug 2014

Go to URL